Show simple item record

dc.contributor.authorZhou, Cong
dc.contributor.authorClamp, Andrew R
dc.contributor.authorBacken, Alison C
dc.contributor.authorBerzuini, Carlo
dc.contributor.authorRenehan, Andrew G
dc.contributor.authorBanks, Rosamonde E
dc.contributor.authorKaplan, Richard
dc.contributor.authorScherer, Stefan J
dc.contributor.authorKristensen, Gunnar B
dc.contributor.authorPujade-Lauraine, Eric
dc.contributor.authorDive, Caroline
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2016-08-19T11:43:41Z
dc.date.available2016-08-19T11:43:41Z
dc.date.issued2016-07-12
dc.identifier.citationSystematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. 2016, 115 (2):228-35 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid27351218
dc.identifier.doi10.1038/bjc.2016.194
dc.identifier.urihttp://hdl.handle.net/10541/618571
dc.description.abstractThere is a critical need for predictive/resistance biomarkers for VEGF inhibitors to optimise their use.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleSystematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.en
dc.typeArticleen
dc.contributor.departmentInstitute of Cancer Sciences, University of Manchester, Manchesteren
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThere is a critical need for predictive/resistance biomarkers for VEGF inhibitors to optimise their use.


This item appears in the following Collection(s)

Show simple item record